Effect of Sevelamer on P-cresyl Sulfate in CKD
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
Price : $35 *
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia; Renal failure
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Design changed from open to randomizes, single blind, parallel; single arm to 2 arms; inclusion/ exclusion criterion changed; second arm is continuously changing between no arm to calcium carbonate, now it is placebo.